These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 20173735)

  • 1. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.
    Fellay J; Thompson AJ; Ge D; Gumbs CE; Urban TJ; Shianna KV; Little LD; Qiu P; Bertelsen AH; Watson M; Warner A; Muir AJ; Brass C; Albrecht J; Sulkowski M; McHutchison JG; Goldstein DB
    Nature; 2010 Mar; 464(7287):405-8. PubMed ID: 20173735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
    Kurosaki M; Tanaka Y; Tanaka K; Suzuki Y; Hoshioka Y; Tamaki N; Kato T; Yasui Y; Hosokawa T; Ueda K; Tsuchiya K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Matsuura K; Sugauchi F; Enomoto N; Nishida N; Tokunaga K; Mizokami M; Izumi N
    Antivir Ther; 2011; 16(5):685-94. PubMed ID: 21817190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.
    El Raziky M; Zayed NA; Abdel Baki A; Mansour SA; Shahin RMH
    J Med Virol; 2017 Oct; 89(10):1823-1829. PubMed ID: 28480960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Genome-wide association study on and the clinical application to chronic hepatitis C].
    Sugiyama M; Mizokami M
    Uirusu; 2011 Jun; 61(1):15-24. PubMed ID: 21972552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.
    Pineda-Tenor D; García-Álvarez M; Jiménez-Sousa MA; Vázquez-Morón S; Resino S
    J Transl Med; 2015 Oct; 13():320. PubMed ID: 26438033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.
    Eskesen AN; Melum E; Moghaddam A; Bjøro K; Verbaan H; Ring-Larsen H; Dalgard O
    Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):890-6. PubMed ID: 22584257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.
    Naggie S; Rallon NI; Benito JM; Morello J; Rodriguez-Novoa S; Clark PJ; Thompson AJ; Shianna KV; Vispo E; McHutchison JG; Goldstein DB; Soriano V
    J Infect Dis; 2012 Feb; 205(3):376-83. PubMed ID: 22158703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment.
    DʼAvolio A; Ciancio A; Siccardi M; Smedile A; Baietto L; Simiele M; Marucco DA; Cariti G; Calcagno A; de Requena DG; Sciandra M; Cusato J; Troshina G; Bonora S; Rizzetto M; Di Perri G
    Ther Drug Monit; 2012 Apr; 34(2):165-70. PubMed ID: 22406654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study).
    Kheloufi F; Poizot-Martin I; Garraffo R; Tavenard A; Quaranta S; Renault A; Lavrut T; Bourlière M; Halfon P; Piroth L; Bellissant E; Lacarelle B; Molina JM; Solas C;
    Antivir Ther; 2017; 22(6):461-469. PubMed ID: 27583701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.
    Thompson AJ; Fellay J; Patel K; Tillmann HL; Naggie S; Ge D; Urban TJ; Shianna KV; Muir AJ; Fried MW; Afdhal NH; Goldstein DB; McHutchison JG
    Gastroenterology; 2010 Oct; 139(4):1181-9. PubMed ID: 20547162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
    Matsuura K; Tanaka Y; Watanabe T; Fujiwara K; Orito E; Kurosaki M; Izumi N; Sakamoto N; Enomoto N; Yatsuhashi H; Kusakabe A; Shinkai N; Nojiri S; Joh T; Mizokami M
    J Viral Hepat; 2014 Jul; 21(7):466-74. PubMed ID: 24750345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients.
    Liu Z; Wang S; Qi W; Wang X; Sun D; Wang H; Zhang Y; Li Z; Zhu L; Zhao P; Guo H; Zhou C; Wang J
    Medicine (Baltimore); 2017 Jul; 96(29):e7554. PubMed ID: 28723780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.
    D'Avolio A; De Nicolò A; Cusato J; Ciancio A; Boglione L; Strona S; Cariti G; Troshina G; Caviglia GP; Smedile A; Rizzetto M; Di Perri G
    Antiviral Res; 2013 Oct; 100(1):114-9. PubMed ID: 23933495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.
    Osinusi A; Naggie S; Poonia S; Trippler M; Hu Z; Funk E; Schlaak J; Fishbein D; Masur H; Polis M; Kottilil S
    J Med Virol; 2012 Jul; 84(7):1106-14. PubMed ID: 22585729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
    Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Oct; 59(4):667-74. PubMed ID: 23707372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection.
    Rau M; Stickel F; Russmann S; Manser CN; Becker PP; Weisskopf M; Schmitt J; Dill MT; Dufour JF; Moradpour D; Semela D; Müllhaupt B; Geier A;
    J Hepatol; 2013 Apr; 58(4):669-75. PubMed ID: 23195617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ITPA gene variant may protect against anemia induced during pegylated interferon alfa and ribavirin combination treatment in Ukrainian patients with chronic hepatitis C.
    Kucherenko A; Pampukha V; Bobrova I ; Moroz L; Livshits L
    Tsitol Genet; 2015; 49(2):38-41. PubMed ID: 26030972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of ITPA gene polymorphisms on the risk of ribavirin-induced haemolytic anaemia using interferon-free antivirals for chronic hepatitis C.
    Esposito I; Benítez-Gutiérrez L; Treviño A; Arias A; Citores MJ; Requena S; Soriano V; Cuervas-Mons V; de Mendoza C
    Antivir Ther; 2017; 22(7):571-575. PubMed ID: 28198349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.
    Di Marco V; Calvaruso V; Grimaudo S; Ferraro D; Pipitone RM; Di Stefano R; Craxì A
    J Viral Hepat; 2013 Feb; 20(2):113-21. PubMed ID: 23301546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.
    Suzuki F; Suzuki Y; Akuta N; Sezaki H; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Chayama K; Kamatani N; Nakamura Y; Miyakawa Y; Kumada H
    Hepatology; 2011 Feb; 53(2):415-21. PubMed ID: 21246582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.